When deciding to build or buy, the key factor is strategic importance. Never cede control of technology that is core to your unique value proposition to a vendor. Reserve outsourcing for necessary but commoditized functions that don't differentiate you in the market.

Enara Bio's discovery platform wasn't outsourced. It was built internally with integrated computational biology, mass spectrometry, and immunology teams. The CEO believes the most significant innovation and "magic" happens at the interface between these disciplines, a synergy only possible with close internal collaboration.

To innovate quickly without being bogged down by technical debt, portfolio companies should ring-fence new AI development. By outsourcing it and treating it as a separate "skunk works" project, the core tech team can focus on existing systems while the new initiative succeeds or fails on its own merits.

Moving technology from academia to a startup requires a crucial mindset shift. The academic goal of publishing data must be replaced by the industry requirement of extensive validation. For Vivtex, this single piece of advice added years of work but was essential for creating a commercially viable platform.

Biotech companies create more value by focusing on de-risking molecules for clinical success, not engineering them from scratch. Specialized platforms can create molecules faster and more reliably, allowing developers to focus their core competency on advancing de-risked assets through the pipeline.

The transition from a resource-rich environment like Novartis to an early-stage biotech reveals a stark contrast. The unlimited access to a global organization is replaced by a total reliance on a small, nimble team where everyone must be multi-skilled and hands-on, a change even experienced executives find jarring.

Boom Supersonic accelerates development by manufacturing its own parts. This shrinks the iteration cycle for a component like a turbine blade from 6-9 months (via an external supplier) to just 24 hours. This rapid feedback loop liberates engineers from "analysis paralysis" and allows them to move faster.

For hard tech startups, the decision to vertically integrate and build a factory shouldn't be automatic. It's a strategic imperative only when "cadence"—the speed of iteration and delivery—is the primary competitive advantage. In such cases, the in-house capability to move fast outweighs the high capital cost.

China's rise in biotech isn't just about cost. It's driven by a tightly integrated ecosystem where drug designers and wet lab technicians work closely, creating a much faster feedback loop than the siloed, outsourced model common in the US.